Ankyra Therapeutics
Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response
Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response
Ankyra Therapeutics is a biotechnology startup founded in 2019 with a vision to revolutionize cancer treatment. The company's flagship approach, coined as Anchored Immunotherapy, aims to harness the power of localized cytokines to trigger a systemic adaptive immune response, holding the potential to combat cancer with minimal systemic toxicity. With its recent $45.00M Series B investment on 12 November 2021, Ankyra has garnered support from prominent investors including GV, Mithril Capital, Polaris Partners, Spring Mountain Capital, Borealis Ventures, Sands Capital Ventures, and Fidelity. This substantial financial backing signifies not only the market's confidence in Ankyra's breakthrough cancer therapy but also the recognition of its innovative potential in the biotechnology landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $45.00M | 7 |
|
12 Nov 2021 |
| Seed Round | $14.50M | 1 |
|
16 May 2020 |
No recent news or press coverage available for Ankyra Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
